截至2026年2月26日收盘，*ST沐邦（603398）报收于9.68元，较前一交易日上涨3.09%，最新总市值为 41.98亿元。该股当日开盘9.39元，最高9.82元，最低9.35元，成交额达8364.75万元，换手率为2.0%。 近日，江西沐邦高科股份有限公司发布《关于预重整进展相关事项的重大风险提示公告》。公告显示， 公司于2025年11月18日被南昌中院决定启动预重整，并指定北京市金杜（深圳）律师事务所担任临时管 理人。公司将于2026年3月13日召开第一次临时债权人会议，提请成立临时债权人委员会，尚未形成实 质性重整方案。公司存在2025年度经审计的净利润为负且营业收入低于3亿元、内控审计被出具非无保 留意见、年报财务数据涉嫌虚假披露被证监会立案调查等重大退市风险。实际控制人廖志远因涉嫌未披 露非经营性资金往来亦被立案调查。公司能否进入重整程序存在重大不确定性。 最新公告列表 《江西沐邦高科股份有限公司关于预重整进展相关事项的重大风险提示公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

深陷诉讼困境的ST香雪近日公告称，公司及其子公司广东高迅医用导管分别向广东南海农村商业银行申请不超过人民币3.693亿元和6810万元的借款重 组，期限一年，用于经营生产。财务数据显示，这家老牌中药企业已连续亏损5年。 公司称，本次借款重组及担保是基于公司及子公司实际经营情况，保证正常运营资金需求，满足经营发展需要的综合考虑，有利于缓解公司及子公司的债 务压力，有助于保障公司的稳定和可持续发展。本次重组借款由子公司广州香岚健康产业有限公司、实际控制人王永辉、陈淑梅提供连带责任担保，并以 公司及香岚健康持有的多处厂房、土地使用权及在建工程作为抵押。 看推文多多留言 有机会获商报君送出的礼品 值得注意的是，ST香雪已深陷诉讼。根据14日公告，公司及控股子公司对合并报表范围内提供担保额度总金额约12.18亿元，占公司最近一期经审计净资 产 115.43%；截至公告披露日，公司对控股子公司担保累计逾期的债务金额合计约11.5亿元（含涉及诉讼的担保金额及因担保被判决败诉而应承担的担保 金额等，具体金额以最终法院判决金额或双方和解金额为准），占公司最近一期经审计净资产108.97%。 ST香雪表示，公司正处于预重整阶段， ...

Recent Events - The company held its 33rd meeting of the 9th Board of Directors on February 13, 2026, to review a proposal for a loan restructuring, seeking up to 369 million yuan from Guangdong Nanhai Rural Commercial Bank for operational development, with guarantees from subsidiaries and actual controllers. This move is related to the ongoing pre-restructuring process, which has been extended twice, with the latest extension until January 11, 2026, but the transition to formal restructuring remains uncertain pending court decisions [2]. Company Status - The company is facing significant litigation pressure, with a total litigation amount of approximately 92.27 million yuan as of February 8, 2026, accounting for 8.78% of the latest audited net assets. This includes a contract dispute with Guangzhou Wanbo Jiacheng Venture Capital of 20.92 million yuan and a financial loan dispute with a bank of 44.96 million yuan, with some cases still unresolved, and the impact on profits is yet to be assessed [3]. Performance and Operations - The company expects a net loss attributable to shareholders of 635 million to 934 million yuan for the full year of 2025, primarily due to high financial expenses, asset impairments, and litigation costs. Given the continuous losses, there is a need to be cautious about the risk of delisting [4].

Recent Events - The restructuring plan of the controlling shareholder, Zhejiang Xiaobei Demei Holdings Co., Ltd., was approved by the creditors' meeting on January 30, 2026, and the management is publicly recruiting potential investors, with a submission deadline of March 4, 2026, at 17:00, requiring a deposit of 80 million yuan [1] - This recruitment may lead to a change in company control, but the company emphasizes its operational independence from the controlling shareholder, stating that production and operations remain unaffected [1] Financial Performance - In the first three quarters of 2025, the company achieved a revenue of 2.033 billion yuan, a year-on-year decrease of 2.6%, while the net profit attributable to shareholders increased by 48.1% to 106 million yuan [2] - However, the net cash flow from operating activities decreased by 68.7% to 103 million yuan, indicating cash flow pressure [2] - The company's non-deductible net profit increased by 76.2%, reflecting an improvement in profitability [2] Company Status - The company announced in January 2025 its intention to use asset pledges to apply for loans, with the pledged asset's net value approximately 987 million yuan [3] - There are also pending lawsuits, including a lawsuit filed in December 2025 seeking to terminate a patent licensing agreement and recover deposits, which may introduce operational uncertainties [3]

Company Dynamics - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (ST Xiangxue) is facing multiple challenges, with over 92.26 million yuan in litigation amounts disclosed in the past year, accounting for 8.78% of the company's latest audited net assets [2] - The company has been involved in significant legal disputes, including a contract dispute amounting to 20.92 million yuan and a financial loan dispute totaling 44.96 million yuan [2] - Established in 1986, ST Xiangxue has developed a full industry chain from traditional Chinese medicine cultivation to production and distribution, with core products including medicinal syrups and granules [2] Financial Performance - Since 2016, ST Xiangxue's net profit has declined significantly, with a drop of over 60% in 2016 to 66.02 million yuan, and subsequent years maintaining net profits between 60 million and 70 million yuan [3] - The company reported a loss of 677 million yuan in 2021, followed by losses of 530 million yuan, 389 million yuan, and 859 million yuan in 2022, 2023, and 2024 respectively [3] - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [3] Restructuring Efforts - The pre-restructuring process was approved by the Guangzhou Intermediate People's Court, initially set for three months but has faced multiple extensions, now extended to January 11, 2026 [3][4] - Despite ongoing restructuring efforts, the company projected a significant loss for 2025, estimating a net loss between 635 million yuan and 934 million yuan [4] - Contributing factors to the losses include intensified market competition, liquidity issues, high financial costs, and asset impairment provisions totaling approximately 130 million yuan [4][5]

Core Viewpoint - ST Xiangxue has been facing significant financial challenges, including ongoing lawsuits and a history of losses, leading to a pre-restructuring process initiated due to its inability to meet debt obligations [1][5][7]. Financial Performance - The company's revenue has declined from over 3 billion yuan in 2020 to over 1.8 billion yuan in 2024 [2]. - The net profit attributable to shareholders has been negative for four consecutive years, with losses of -677 million yuan, -530 million yuan, -389 million yuan, and -859 million yuan from 2021 to 2024 [2]. - The cumulative non-recurring net profit from 2017 to 2024 is approximately -2.511 billion yuan, with only one profitable year in 2020 [2]. 2025 Performance Forecast - For 2025, the company expects a net profit loss between 635 million yuan and 934 million yuan, compared to a loss of 859 million yuan in the previous year [2]. - The anticipated non-recurring net profit loss for 2025 is projected to be between 612 million yuan and 899 million yuan [2]. Factors Affecting Performance - The company faces significant financial burdens, including short-term and long-term borrowings amounting to approximately 250 million yuan in financial expenses [3]. - Fixed asset depreciation and amortization are expected to impact around 200 million yuan [3]. - Asset impairment tests are projected to require approximately 130 million yuan for inventory, construction in progress, fixed assets, and development expenditures [3]. - Legal and overdue interest expenses are estimated to be around 220 million yuan [4]. - Non-recurring gains and losses are expected to influence net profit by about 30 million yuan [5]. Pre-restructuring Process - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [5]. - The pre-restructuring period was initially set for three months but has been extended multiple times, with the latest extension to January 11, 2026 [5]. Regulatory Issues - The company has faced administrative penalties for information disclosure violations, resulting in a fine of 6 million yuan and warnings to its actual controller [7]. - The stock was suspended for one day due to these violations and has been placed under risk warnings, changing its name to ST Xiangxue [7]. Market Performance - As of February 6, ST Xiangxue's stock price was 9.50 yuan per share, with a total market capitalization of 6.282 billion yuan [8].

Core Viewpoint - The company is undergoing bankruptcy reorganization due to its inability to repay debts and is deemed to have restructuring value [1] Group 1: Legal Proceedings - On July 8, 2025, the company received a notification from the Beijing First Intermediate People's Court regarding a bankruptcy reorganization application filed by creditor Beijing Guofeng Jianye Construction Engineering Co., Ltd. [1] - The court decided to initiate pre-reorganization on July 10, 2025, and appointed Dongfang Shishang Driving School Co., Ltd. as the temporary administrator during the pre-reorganization period [1] Group 2: Disclosure of Progress - The company disclosed relevant progress announcements on August 9, September 10, October 10, November 8, December 9, and January 9, 2026 [1]

Core Viewpoint - Tianbang Food has set a target to reduce its full cost of fattening pigs to 13.31 yuan/kg in 2025, achieving a decrease of 1.89 yuan/kg year-on-year, while facing a projected net loss of 1.11 billion to 1.31 billion yuan for the same year [2][3] Group 1: Cost Reduction and Sales Performance - The full cost of fattening pigs in December 2025 was reported at 12.92 yuan/kg, and after excluding empty pen costs, it was 12.6 yuan/kg, meeting the cost reduction target set at the beginning of 2025 [2] - The company expects to sell 6.6635 million pigs in 2025, including 2.3936 million piglets, marking an 11.21% increase in sales volume year-on-year (8.7% increase excluding piglets) [2] - The average selling price of commodity pigs in 2025 is projected to be 14.65 yuan/kg, a decrease of 17.85% compared to the average price of 17.84 yuan/kg in 2024 [2] Group 2: Financial Challenges and Impairment Provisions - The company anticipates total interest expenses of approximately 350 million yuan and costs related to unutilized or vacant pig farms of about 325 million yuan, which together will reduce the total profit by approximately 675 million yuan, translating to an average cost of 101 yuan per pig sold in 2025 [2] - Tianbang Food plans to recognize asset impairment provisions for assets showing signs of impairment, expecting to reduce total profit by 761 million to 938 million yuan for the year [3] Group 3: Operational Adjustments and Cash Flow - The company is currently in a pre-restructuring phase, which is a procedure before formal court restructuring, and the outcome of this restructuring remains uncertain [3] - Despite the challenges, the company is actively working on operational optimization and improving cash flow, with an expected net operating cash flow of 850 million to 950 million yuan for the year, which includes repayments of 248 million yuan to farmers [3]

Core Viewpoint - The announcement from Beiyinmei reveals that its controlling shareholder, Zhejiang Xiaobei Damei Holdings, has passed a pre-restructuring plan, indicating potential changes in control and future uncertainties for the company [1][2]. Group 1: Restructuring and Control Changes - The pre-restructuring plan was approved by specific creditor groups, allowing for the continuation of restructuring efforts, although the success of the restructuring remains uncertain [2][8]. - The restructuring aims to help the company recover by introducing strategic investors and debt swaps, with the approval signaling initial support from creditors for the proposed restructuring path [2][8]. - The potential change in control may lead to new development strategies and personnel arrangements, but the management's primary responsibility will be to maintain operational stability [3][7]. Group 2: Financial Challenges and Historical Context - Xiaobei Damei Holdings holds 12.28% of Beiyinmei's total shares, with 98.85% of these shares pledged or frozen, highlighting a precarious equity situation [3][4]. - Beiyinmei, once a leader in the domestic milk powder industry, has seen a significant decline in revenue from 61.17 billion in 2013 to 24.91 billion in 2018, with substantial losses totaling over 1.8 billion during 2016-2017 [4][5]. - The company's financial imbalance has been a long-term issue, exacerbated by aggressive credit policies that increased accounts receivable from 425 million in 2014 to 1.363 billion in 2015, leading to severe cash flow issues [4][5]. Group 3: Market Concerns and Future Outlook - Concerns are rising regarding the impact of the controlling shareholder's restructuring on the stability of the management and the strategic coherence of Beiyinmei, especially during its transformation phase [6][7]. - Despite the ongoing challenges, Beiyinmei has emphasized that its production and operational status remain normal, and the restructuring will not significantly affect daily operations [7][8]. - The approval of the pre-restructuring plan opens a new chapter in the debt crisis narrative, but the outcome of the formal restructuring process and its implications for control and strategy remain uncertain [8].

Core Viewpoint - Zhejiang Bangjie Holdings Group Co., Ltd. is at risk of being delisted due to negative net assets and negative net profits for the upcoming fiscal year, which may lead to the implementation of risk warnings on its stock trading [1][2][3]. Group 1: Financial Performance - The company estimates that by the end of 2025, the net assets attributable to shareholders will be between -900.1551 million and -600.1551 million (unaudited) [2]. - The projected net profit for 2025 is expected to be between -1.2 billion and -900 million, with the net profit after excluding non-recurring gains and losses estimated to be between -1.08 billion and -780 million [3][11]. - The company has reported negative net profits for the last three fiscal years, and the 2024 financial report included a significant uncertainty regarding its ability to continue as a going concern [3][11]. Group 2: Regulatory Compliance - According to the Shenzhen Stock Exchange's listing rules, if the company’s audited net assets are negative, it will face delisting risk warnings after the 2025 annual report is disclosed [1][4]. - The company is required to issue risk warning announcements if it anticipates conditions that may lead to delisting or other risk warnings, with specific timelines for disclosure [2][4]. Group 3: Operational Challenges - The company is facing significant operational challenges, primarily due to debt pressures from its photovoltaic subsidiary and production halts, leading to substantial fixed costs [11]. - The company is currently undergoing a pre-restructuring process, although it remains uncertain whether it will enter formal restructuring proceedings [5][15].